Aquarius Biotechnologies
Aquarius uses a drug delivery technology to allow oral delivery of drugs that are now only available via IV, and reduce drug toxicity.
- Stage Full Product Ready
- Industry Biotechnology
- Location Chicago, IL, USA
- Currency USD
- Founded June 2012
- Employees 5
- Website aquariusbio.com
Company Summary
Many drugs exist that are effective in treating diseases, but are difficult and expensive to administer with existing technology. In addition, many of these drugs are highly toxic and have a short shelf-life. Aquarius' technology, called "cochleate" technology, solves these problems by delivering the drugs more cheaply and effectively with less toxicity. Aquarius partners with pharma and biotech companies to develop drugs using the technology.
Team
-
Raphael Thomas ManninoChief Executive Officer
7 years general management experience
Former Associate, Hyde Park Angels and Hyde Park Venture Partners
MBA (in progress), University of Chicago Booth School of Business
B.A. Mathematics, Columbia University -
Raphael James ManninoChief Scientific Officer
Inventor of cochleate technology
Founder of biotech company that is now publicly traded
Professor, University of Medicine and Dentistry of New Jersey
Ph.D. in Biological Chemistry, Johns Hopkins School of Medicine -
Carl CraftChief Medical Officer
Designed over 100 clinical trials
15+ yrs leading anti-infective unit at Abbott Laboratories
Scientific Advisory Board, Drugs for Neglected Disease Initiative -
Ruying LuChief Formulations Scientist
World’s foremost expert in cochleate formulation (15+ years)
Inventor on 5 issued patents
Graduate of Shanghai Second Medical University -
Susan BonitzChief Development Officer
20 years experience with start-ups and big pharma
10+ years working with government agencies to secure grants
Ph.D. in Molecular Biology, Columbia University
Advisors
-
McCarter & EnglishLawyerUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.